File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: From laboratory discovery to clinical evaluation

TitleTraditional Chinese herbal medicines for treatment of liver fibrosis and cancer: From laboratory discovery to clinical evaluation
Authors
KeywordsApoptosis
Berberine
Celastrol
Cirrhosis
Curcumin
Glycyrrhizin
Hepatitis
Livercancer
Oxymatrine
Salvianolic acids
Signalling
Stellate cells
Tetrandrine
Triptolide
Issue Date2007
PublisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1
Citation
Liver International, 2007, v. 27 n. 7, p. 879-890 How to Cite?
AbstractLiver disease afflicts over 10% of the world population. This includes chronic hepatitis, alcoholic steatosis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC), which are the most health-threatening conditions drawing considerable attention from medical professionals and scientists. Patients with alcoholism or viral hepatitis are much more likely to have liver cell damage and cirrhosis, and some may eventually develop HCC, which is unfortunately, and very often, a fatal malignancy without cure. While liver surgery is not suitable in many of the HCC cases, patients are mostly given palliative support cares or transarterial chemoembolization or systemic chemotherapies. However, HCC is well known to be a highly chemoresistant tumour, and the response rate is <10-20%. To this end, alternative medicines are being actively sought from other sources with hopes to halt the disease's progression or even eliminate the tumours. Traditional Chinese herbal medicine has begun to gain popularity worldwide for promoting healthcare as well as disease prevention, and been used as conventional or complementary medicines for both treatable and incurable diseases in Asia and the West. In this article, we discuss the laboratory findings and clinical trial studies of Chinese herbal medicines (particularly small molecule compounds) for the treatment of liver disease ranging from fibrosis to liver cancer. © 2007 Blackwell Munksgaard.
Persistent Identifierhttp://hdl.handle.net/10722/83539
ISSN
2015 Impact Factor: 4.47
2015 SCImago Journal Rankings: 1.677
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLuk, JMen_HK
dc.contributor.authorWang, Xen_HK
dc.contributor.authorLiu, Pen_HK
dc.contributor.authorWong, KFen_HK
dc.contributor.authorChan, KLen_HK
dc.contributor.authorTong, Yen_HK
dc.contributor.authorHui, CKen_HK
dc.contributor.authorLau, GKen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-06T08:42:14Z-
dc.date.available2010-09-06T08:42:14Z-
dc.date.issued2007en_HK
dc.identifier.citationLiver International, 2007, v. 27 n. 7, p. 879-890en_HK
dc.identifier.issn1478-3223en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83539-
dc.description.abstractLiver disease afflicts over 10% of the world population. This includes chronic hepatitis, alcoholic steatosis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC), which are the most health-threatening conditions drawing considerable attention from medical professionals and scientists. Patients with alcoholism or viral hepatitis are much more likely to have liver cell damage and cirrhosis, and some may eventually develop HCC, which is unfortunately, and very often, a fatal malignancy without cure. While liver surgery is not suitable in many of the HCC cases, patients are mostly given palliative support cares or transarterial chemoembolization or systemic chemotherapies. However, HCC is well known to be a highly chemoresistant tumour, and the response rate is <10-20%. To this end, alternative medicines are being actively sought from other sources with hopes to halt the disease's progression or even eliminate the tumours. Traditional Chinese herbal medicine has begun to gain popularity worldwide for promoting healthcare as well as disease prevention, and been used as conventional or complementary medicines for both treatable and incurable diseases in Asia and the West. In this article, we discuss the laboratory findings and clinical trial studies of Chinese herbal medicines (particularly small molecule compounds) for the treatment of liver disease ranging from fibrosis to liver cancer. © 2007 Blackwell Munksgaard.en_HK
dc.languageengen_HK
dc.publisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1en_HK
dc.relation.ispartofLiver Internationalen_HK
dc.subjectApoptosisen_HK
dc.subjectBerberineen_HK
dc.subjectCelastrolen_HK
dc.subjectCirrhosisen_HK
dc.subjectCurcuminen_HK
dc.subjectGlycyrrhizinen_HK
dc.subjectHepatitisen_HK
dc.subjectLivercanceren_HK
dc.subjectOxymatrineen_HK
dc.subjectSalvianolic acidsen_HK
dc.subjectSignallingen_HK
dc.subjectStellate cellsen_HK
dc.subjectTetrandrineen_HK
dc.subjectTriptolideen_HK
dc.titleTraditional Chinese herbal medicines for treatment of liver fibrosis and cancer: From laboratory discovery to clinical evaluationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1478-3223&volume=27&issue=7&spage=879&epage=890.&date=2007&atitle=Traditional+Chinese+herbal+medicines+for+treatment+of+liver+fibrosis+and+cancer:+from+laboratory+discovery+to+clinical+evaluationen_HK
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_HK
dc.identifier.emailTong, Y: tongyao@hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityLuk, JM=rp00349en_HK
dc.identifier.authorityChan, KL=rp00572en_HK
dc.identifier.authorityTong, Y=rp00509en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1478-3231.2007.01527.xen_HK
dc.identifier.pmid17696925-
dc.identifier.scopuseid_2-s2.0-34547908170en_HK
dc.identifier.hkuros137596en_HK
dc.identifier.hkuros137092-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34547908170&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume27en_HK
dc.identifier.issue7en_HK
dc.identifier.spage879en_HK
dc.identifier.epage890en_HK
dc.identifier.isiWOS:000249289500001-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLuk, JM=7006777791en_HK
dc.identifier.scopusauthoridWang, X=11639883200en_HK
dc.identifier.scopusauthoridLiu, P=36065603800en_HK
dc.identifier.scopusauthoridWong, KF=35081410800en_HK
dc.identifier.scopusauthoridChan, KL=37004089600en_HK
dc.identifier.scopusauthoridTong, Y=9045384000en_HK
dc.identifier.scopusauthoridHui, CK=14054127700en_HK
dc.identifier.scopusauthoridLau, GK=7102301257en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.citeulike1561894-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats